Table 3.
Substrate | Sequence | Enzyme | Km (mM) | kcat (s−1) | kcat/Km (mM−1s−1) | Activty (%) relative to PR | Order of cleavagea |
---|---|---|---|---|---|---|---|
MA/CA | VSQNY↓PIVQ | PR | 0.15 | 6.9 | 46.0 | 2 | |
PR20 | 0.91 | 3.0 | 3.2 | 7 | 1 | ||
CA/SP1 | KARVL↓AEAMS | PR | 0.02 | 0.9 | 42.4b | 3 | |
PR20 | 0.11 | 0.1 | 1.2 | 2.8 | 3 | ||
SP1/NC | TATIM↓MQRGN | PR | 0.10 | 6.7 | 67.0 | 1 | |
PR20 | 0.10 | 0.2 | 2.0 | 3.0 | 2 | ||
NC/SP2 | ERQAN↓FLGKI | PR | 0.17 | 0.15 | 0.9c | 5 | |
PR20 | 0.23 | 0.0005 | 0.002 | 0.2 | 6 | ||
NC/SP2 mutant | ERRVN↓FLGKI | PR | nd | nd | 20.1c | 4 | |
PR20 | 0.23 | 0.01 | 0.04 | 0.2 | 4 | ||
SP2/p6 | RPQNF↓LQSRP | PR | 0.48 | 0.4 | 0.8 | 6 | |
PR20 | 0.43 | 0.01 | 0.02 | 2.5 | 5 |